New antibody drug GR2301 begins first human safety tests
NCT ID NCT07190716
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tests a single injection of GR2301, an antibody that targets IL15, in 36 healthy adults in China. The main goal is to check safety and how the body processes the drug. Participants are randomly assigned to receive either GR2301 or a placebo, and are monitored for at least 16 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GR2301 (IL15 monoclonal antibody)
What this could lead to
If successful, this early safety data could support further studies of GR2301 for immune-related diseases.
What could go wrong
This is a very early Phase 1 trial in only 36 healthy people, so it cannot yet show if the drug works for any disease. Side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tongren Hospital Affiliated to Capital Medical University
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact